Edgewise Therapeutics Shares Outstanding vs. Debt To Equity
| EWTX Stock | USD 31.98 0.22 0.68% |
For Edgewise Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Edgewise Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Edgewise Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Edgewise Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Edgewise Therapeutics over time as well as its relative position and ranking within its peers.
Edgewise |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edgewise Therapeutics. If investors know Edgewise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edgewise Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.50) | Return On Assets (0.22) | Return On Equity (0.32) |
The market value of Edgewise Therapeutics is measured differently than its book value, which is the value of Edgewise that is recorded on the company's balance sheet. Investors also form their own opinion of Edgewise Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Edgewise Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edgewise Therapeutics' market value can be influenced by many factors that don't directly affect Edgewise Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edgewise Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edgewise Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edgewise Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Edgewise Therapeutics Debt To Equity vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Edgewise Therapeutics's current stock value. Our valuation model uses many indicators to compare Edgewise Therapeutics value to that of its competitors to determine the firm's financial worth. Edgewise Therapeutics is rated # 2 in shares outstanding category among its peers. It is rated # 3 in debt to equity category among its peers . The ratio of Shares Outstanding to Debt To Equity for Edgewise Therapeutics is about 13,526,928,000 . At this time, Edgewise Therapeutics' Debt To Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Edgewise Therapeutics' earnings, one of the primary drivers of an investment's value.Edgewise Debt To Equity vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Edgewise Therapeutics |
| = | 94.69 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Edgewise Therapeutics |
| = | 0.01 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Edgewise Debt To Equity Comparison
Edgewise Therapeutics is currently under evaluation in debt to equity category among its peers.
Edgewise Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Edgewise Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Edgewise Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Edgewise Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Edgewise Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 99 K | 104 K | |
| Net Interest Income | 14.2 M | 14.9 M | |
| Interest Income | 14.2 M | 14.9 M | |
| Operating Income | -114.4 M | -108.6 M | |
| Net Loss | -100.2 M | -95.2 M | |
| Income Before Tax | -100.2 M | -95.2 M | |
| Total Other Income Expense Net | 14.2 M | 14.9 M | |
| Net Loss | -60.9 M | -57.8 M | |
| Net Loss | -100.2 M | -95.2 M | |
| Income Tax Expense | -3.6 M | -3.4 M | |
| Non Operating Income Net Other | 4.6 M | 2.4 M | |
| Change To Netincome | 12.6 M | 13.2 M | |
| Net Loss | (1.57) | (1.49) | |
| Income Quality | 0.92 | 0.95 | |
| Net Income Per E B T | 0.91 | 1.03 |
Edgewise Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Edgewise Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Edgewise Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Edgewise Therapeutics' important profitability drivers and their relationship over time.
Use Edgewise Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edgewise Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edgewise Therapeutics will appreciate offsetting losses from the drop in the long position's value.Edgewise Therapeutics Pair Trading
Edgewise Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Edgewise Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edgewise Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edgewise Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edgewise Therapeutics to buy it.
The correlation of Edgewise Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edgewise Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edgewise Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edgewise Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Edgewise Therapeutics position
In addition to having Edgewise Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Heavy Metals Thematic Idea Now
Heavy Metals
Companies involved in mining, production, and distribution of various industrial metals and minerals. The Heavy Metals theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Heavy Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.